BioNxt Solutions Advances Toward Human Trials with Promising Drug Data

Bionxt Solutions CA0909741062

BioNxt Solutions Inc. has reported a significant milestone in its pharmaceutical development program. The Canadian biotechnology firm announced positive outcomes from a comparative pharmacokinetic study, indicating that its proprietary formulation of cladribine outperformed an established reference product. This progress brings the company closer to initiating clinical trials in human subjects.

The development places BioNxt squarely within the expanding market for multiple sclerosis (MS) therapies, a sector projected to surpass $41 billion by 2033. The reference drug, Mavenclad, already generates annual global revenues exceeding one billion dollars. BioNxt’s strategy centers on a value-added reformulation of a proven active ingredient. Its sublingual oral dissolvable film (ODF) requires no swallowing, addressing a common challenge for patients with neurodegenerative conditions like MS who experience dysphagia. Furthermore, the potential for a lower required dosage could reduce side effects while maintaining therapeutic efficacy.

Study Demonstrates Superior Drug Delivery

Data released on Monday, derived from a porcine model selected for its physiological relevance to humans, compared BioNxt's sublingual ODF to the commercially available cladribine tablet, Mavenclad.

Key findings from the research include:

• The ODF formulation demonstrated a higher bioavailability than the reference tablet under test conditions.
• Blood concentration levels were measured over a 24-hour period following a single dose equivalent to 5mg of cladribine.
• The results support the hypothesis that sublingual administration can achieve therapeutic blood levels with a potentially lower total dose.

Chief Executive Hugh Rogers stated he was "extremely encouraged" by the results. The company is now conducting an internal review of the complete dataset to optimize the dosage for upcoming phases of study.

Path Forward: Human Trials and Patent Portfolio

The next critical step for BioNxt is a comparative bioequivalence study in humans, which is scheduled to commence in the first quarter of 2026. The data from this recent large-animal study will directly inform the dosing strategy for that pivotal testing phase. In parallel, the company anticipates receiving final national-level patent grants for its ODF platform technology in the near term. BioNxt Solutions shares trade on the Canadian Securities Exchange under the ticker symbol BNXT.